Key Insights

Highlights

Success Rate

56% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

14.3%

4 terminated out of 28 trials

Success Rate

55.6%

-30.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results56% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (2)
Early P 1 (4)
P 1 (4)
P 2 (7)

Trial Status

Unknown8
Recruiting5
Completed5
Terminated4
Active Not Recruiting3
Withdrawn2

Trial Success Rate

55.6%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (28)

Showing 20 of 20 trials
NCT07547163Recruiting

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared

NCT03728673Phase 2RecruitingPrimary

A Study Utilizing Escitalopram in Glioma Patients

NCT03935685Phase 2Active Not RecruitingPrimary

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

NCT03698162Not ApplicableTerminated

Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases

NCT03739372Not ApplicableActive Not Recruiting

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

NCT03698201TerminatedPrimary

Blood Biomarker Signature in Glioma

NCT03834740Early Phase 1Completed

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

NCT03665545Phase 1Completed

Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

NCT03496181Completed

Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently

NCT03213002Phase 1Recruiting

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

NCT03849430RecruitingPrimary

Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients

NCT03189420Active Not RecruitingPrimary

Glioma Microenvironment an Exploratory Study

NCT03763396Early Phase 1Not Yet Recruiting

Azoles Targeting Recurrent High Grade Gliomas

NCT03194906Phase 2CompletedPrimary

Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

NCT03779230Phase 1CompletedPrimary

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

NCT03927274Early Phase 1TerminatedPrimary

Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

NCT03534050Phase 2RecruitingPrimary

Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy

NCT03436433Phase 2Terminated

Seizure Prophylaxis in Patients With Glioma or Brain Metastasis

NCT03796507Early Phase 1WithdrawnPrimary

Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation

NCT04406610Phase 1WithdrawnPrimary

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Scroll to load more

Research Network

Activity Timeline